We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-19.62%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$966M
AUM Growth
-$102M
Cap. Flow
+$140M
Cap. Flow %
14.53%
Top 10 Hldgs %
64.34%
Holding
33
New
2
Increased
11
Reduced
6
Closed
–

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$64.4M
2
BLUE
bluebird bio
BLUE
+$28.3M
3
CDNA icon
CareDx
CDNA
+$22.2M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$18.2M
5
FULC icon
Fulcrum Therapeutics
FULC
+$9.34M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$9.04M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.96M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$3.58M
4
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$2.15M
5
EDIT icon
Editas Medicine
EDIT
+$1.61M

Sector Composition

Rank Sector Weight
1 Healthcare 81.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONCE
1
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$83.7M 8.66%
863,300
-21,500
-2% -$2.15M
NVTA
2
DELISTED
Invitae Corporation
NVTA
$74M 7.65%
3,838,388
– –
CDXS icon
3
Codexis
CDXS
$157M
$69.6M 7.2%
5,073,780
– –
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$69.1M 7.15%
940,000
– –
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.63B
$66.3M 6.86%
880,000
+545,000
+163% +$64.4M
MYOK
6
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$58.1M 6.02%
1,115,000
-170,000
-13% -$9.04M
BLUE
7
DELISTED
bluebird bio
BLUE
$56.2M 5.82%
47,285
+18,528
+64% +$28.3M
SAGE
8
DELISTED
Sage Therapeutics
SAGE
$56.1M 5.81%
400,000
– –
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$29.1B
$48.3M 4.99%
600,000
-50,000
-8% -$3.96M
BLFS icon
10
BioLife Solutions
BLFS
$1.56B
$40.4M 4.18%
2,428,571
– –
FATE icon
11
Fate Therapeutics
FATE
$294M
$39.6M 4.1%
2,550,000
– –
DNTH icon
12
Dianthus Therapeutics
DNTH
$5.72B
$31.3M 3.24%
190,508
+2,813
+1% +$534K
AGIO icon
13
Agios Pharmaceuticals
AGIO
$1.84B
$30.3M 3.14%
935,000
+440,000
+89% +$18.2M
BOLD
14
DELISTED
Audentes Therapeutics, Inc
BOLD
$24.2M 2.5%
860,000
-105,000
-11% -$3.58M
CDNA icon
15
CareDx
CDNA
$2.48B
$22.6M 2.34%
1,000,000
+800,000
+400% +$22.2M
GNMK
16
DELISTED
GenMark Diagnostics, Inc
GNMK
$20.4M 2.11%
3,365,000
– –
VYGR icon
17
Voyager Therapeutics
VYGR
$179M
$19.4M 2.01%
1,128,075
– –
ILMN icon
18
Illumina
ILMN
$30.2B
$18.3M 1.89%
61,680
– –
GRTS
19
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$15.3M 1.58%
1,770,000
– –
QTTB icon
20
Q32 Bio
QTTB
$460M
$14.8M 1.54%
45,556
+4,167
+10% +$1.42M
GBT
21
DELISTED
Global Blood Therapeutics, Inc.
GBT
$14.6M 1.51%
300,000
– –
ADPT icon
22
Adaptive Biotechnologies
ADPT
$3.71B
$14.3M 1.48%
463,125
– –
SGMO
23
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$13.2M 1.36%
1,455,000
-75,000
-5% -$841K
ALEC icon
24
Alector
ALEC
$168M
$11.7M 1.21%
811,039
+260,000
+47% +$4.69M
DNLI icon
25
Denali Therapeutics
DNLI
$3.67B
$9.96M 1.03%
650,000
+250,000
+63% +$4.78M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q3 2019 Portfolio in Review

As of Q3 2019, Casdin Capital held 33 positions worth $966M, down 9.6% from $1.07B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Casdin Capital deployed $140M of net new capital in Q3 2019, opening 2 new positions and adding to 11 existing holdings. Its largest new stake was Fulcrum Therapeutics: 844,285 shares worth $5.61M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 81% a quarter earlier.

On the sell side, the largest reduction was MyoKardia, Inc. Common Stock, an estimated $9.04M trimmed.

  • Casdin Capital's largest Q3 2019 buy was Fulcrum Therapeutics: 844,285 shares worth $5.61M.
  • Casdin Capital added most to Sarepta Therapeutics in Q3 2019, an estimated $64.4M increase.
  • Casdin Capital's biggest Q3 2019 reduction was MyoKardia, Inc. Common Stock, cutting an estimated $9.04M.
  • Casdin Capital's ten largest holdings make up 64% of its $966M portfolio in Q3 2019.
  • Casdin Capital opened 2 new positions and closed 0 in Q3 2019.
  • Casdin Capital's portfolio value fell 9.6% quarter-over-quarter to $966M.

Based on Casdin Capital's 13F filing for Q3 2019, filed 12 Nov 2019.